EHA 2026: Early Curative Treatment in Pediatric Sickle Cell Disease and Thalassemia

At EHA 2026 Congress, Cecilia Langenskiöld, MD, Senior Consultant in Pediatric Hematology and Oncology at Queen Silvia Children’s Hospital, Gothenburg, Sweden, discusses curative treatment options for children with sickle cell disease and thalassemia. She highlights the importance of early intervention, as treatment before adulthood may prevent long-term disease-related complications. Langenskjöld also addresses allogeneic stem cell transplantation and key pediatric considerations, including fertility preservation and long-term treatment planning.